Stifel Reiterates Buy on Viking Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy has reiterated a 'Buy' rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $30.
August 08, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst has reiterated a 'Buy' rating on Viking Therapeutics and maintained a price target of $30.
The reiteration of a 'Buy' rating and maintenance of a high price target by a Stifel analyst indicates strong confidence in Viking Therapeutics. This could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100